Latest Industry Insights

How can the industry as a whole address sustainability issues? What are the key needs and goals of pharma and biopharma laboratories when it comes to sustainability?

HPLC system manufacturers have been striving to improve usability, accessibility and help users improve their experimental outcomes. And what better way to do that than to involve the users themselves in that development process.

Dr. Andreas Boehmler explores how the arrival of new flow cytometry platforms finally puts powerful automation within reach for many labs, allowing operators to enumerate stem cells more quickly and accurately for transplant.

Explore the importance of location-specific expertise in global research collaborations and how to overcome challenges faced by in-house R&D teams when engaging with global partners.

To learn more about the waters_connect^TM System Monitoring Software and the benefits it offers, Technology Networks spoke to Dave Leitham.

We spoke to Prof. Oscar Ces, head of the Department of Chemistry at Imperial College London (ICL), to find out about the evolution of ICL’s White City Campus, the Agilent Measurement Suite and what it means for scientists across the board.

Revvity announced its newly established Scientific Centre of Excellence in Cambridge, where scientists can outsource their research needs to Revvity experts. Technology Networks visited the site to learn more about how Revvity is supporting its customers in their drug discovery efforts.

New applications for RNA therapeutics are continuously emerging. In this burgeoning space, nucleic acid quantification can help this dynamic therapeutic modality reach its full potential.

Technology Networks spoke with Ken Suzuki and Jennifer Gushue to learn more about how Agilent is addressing customer needs with novel “intelligence” features and the company’s efforts to ensure the sustainability and longevity of its products

Unlocking more information from our proteome could deepen our understanding of disease, improve detection and influence drug selection. To find out more about single-molecule proteomics, we spoke to Parag Mallick, co-founder of Nautilus Biotech.